Hanmi Pharm registers International Nonproprietary Name for its new immune disorder treatment

Published: 2017-03-09 13:29:26

Updated: 2017-03-09 13:29:26

Hanmi Pharm(CEO Gwan-Sun Lee) decided a name of the self-developed new drug ‘HM71224’ for the treatment of immune system disorder on ‘Poseltinib.’

Hanmi Pharm announced on the 7^th ‘Poseltinib’ was recently registered as the International Nonproprietary Name(INN), an official name given by the World Health Organization to distinguish pharmaceutical products.

Poseltinib, a substance licensed ou...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.